Your browser doesn't support javascript.
loading
Montelukast suppresses the development of irritable bowel syndrome phenotype possibly through modulating NF-κB signaling in an experimental model.
Khodabakhsh, Pariya; Khoie, Nilgoon; Dehpour, Ahmad-Reza; Abdollahi, Alireza; Ghazi-Khansari, Mahmoud; Shafaroodi, Hamed.
Afiliação
  • Khodabakhsh P; Student Research Committee, Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Khoie N; Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Dehpour AR; Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Abdollahi A; Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Ghazi-Khansari M; Department of Pathology, School of Medicine, IKHC, Teheran University of Medical Sciences, Tehran, Iran.
  • Shafaroodi H; Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Inflammopharmacology ; 30(1): 313-325, 2022 Feb.
Article em En | MEDLINE | ID: mdl-35013876

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndrome do Intestino Irritável Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Inflammopharmacology Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Irã

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndrome do Intestino Irritável Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Inflammopharmacology Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Irã